Eurosurveillance banner




Announcements
Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Edition  2011: Volume 16/ Issue 43 Article 4 Printer friendly version
Back to Table of Contents
Previous Download (pdf) Next

Eurosurveillance, Volume 16, Issue 43, 27 October 2011
Research articles
Highly heterogeneous temperature sensitivity of 2009 pandemic influenza A(H1N1) viral isolates, northern France
  1. Institut Pasteur, Unité de Biologie des Virus Entériques, Département de Virologie, Paris, France
  2. INSERM U994 (French National Institute of Health and Medical Research) Paris, France
  3. Institut Pasteur, Unité de Génétique Moléculaire des virus à ARN, Département de Virologie, Paris, France
  4. CNRS URA3015 (French National Centre for Scientific Research), Paris, France
  5. Université Paris Diderot, Sorbonne Paris Cité, Unité de Génétique Moléculaire des virus à ARN, Paris, France
  6. Institut Pasteur, Centre National de Référence des virus influenzae (Région Nord), Paris, France
  7. Groupes Régionaux d'Observation de la Grippe, Open Rome, Paris, France

Citation style for this article: Pelletier I, Rousset D, Enouf V, GROG, Colbère-Garapin F, van der Werf S, Naffakh N. Highly heterogeneous temperature sensitivity of 2009 pandemic influenza A(H1N1) viral isolates, northern France. Euro Surveill. 2011;16(43):pii=19999. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19999
Date of submission: 19 July 2011

We assayed the temperature sensitivity of 2009 pandemic influenza A(H1N1) viral isolates (n=23) and seasonal influenza A(H1N1) viruses (n=18) isolated in northern France in 2007/08 and 2008/09. All isolates replicated with a similar efficiency at 34 °C and 37 °C, and with a lower efficiency at 40 °C. The pandemic viral isolates showed a stronger heterogeneity in their ability to grow at the highest temperature, as compared with the seasonal isolates. No statistically significant difference in temperature sensitivity was observed between the pandemic viral isolates from severe and mild cases of influenza. Our data point to the impact of temperature sensitivity on the genetic evolution and diversification of the pandemic influenza A(H1N1) virus since its introduction into the human population in April 2009, and call for close surveillance of this phenotypic marker related to host and tissue tropism.


Introduction

A novel influenza A(H1N1) virus emerged in April 2009 [1-3] and rapidly spread all over the world. In France, the first cases were identified in early May 2009. The 2009 pandemic A(H1N1) virus presented a unique combination of genomic segments that had not been reported previously [4]. The segments coding for the neuraminidase (NA) and the matrix (M) proteins of the virus were related to the Eurasian lineage of swine influenza A(H1N1) viruses, whereas the six remaining gene segments were related to triple swine–human–avian influenza A(H1N1) reassortants that have been isolated from humans in contact with pigs in North America since 1998 [5,6]. Although the properties of isolates of the 2009 pandemic influenza A(H1N1) virus have already been largely examined in vitro and in vivo (for a review, see [7]), sensitivity to elevated temperature has not been characterised precisely. Temperature sensitivity is an important viral phenotypic marker, as it may be involved in host species restriction, tissue specificity and/or virulence [8-11]. In humans and pigs, influenza A viruses initially replicate in the upper respiratory tract at temperatures close to 33 °C and 37 °C, respectively, whereas in aquatic birds, influenza A viruses with low pathogenicity preferentially replicate in the intestinal tract at a temperature close to 40 °C [12-14]. The sensitivity of avian influenza A viruses to low temperature (33 °C) has been clearly demonstrated [15,16]. In contrast, no reduction in viral multiplication at 33 °C was observed for the swine viruses, and it has been proposed that temperature sensitivity might represent a specific, host-dependent signature of influenza A viruses [17]. Depending on the optimal temperature for viral multiplication, fever in infected patients may either limit or facilitate viral multiplication and consequently the administration of anti-pyretic drugs may or not be beneficial. Treatment of ferrets infected with influenza virus with sodium salicylate (an anti-pyretic) resulted in increased viral loads in nasal washes [18].

In order to characterise and compare the temperature sensitivity of both pandemic influenza A(H1N1) viral isolates and seasonal viruses isolated in northern France in 2007/08 and 2008/09 before the emergence of the pandemic virus, we developed a test to compare viral multiplication at 34 °C, 37 °C and 40 °C.

Methods

Virus samples and reference isolates
We included 23 isolates of 2009 pandemic influenza A(H1N1) virus and 18 seasonal influenza A(H1N1) viral isolates in our study. The pandemic isolates were collected in northern France between weeks 39 and 51 (24 September to 16 December) in 2009; pandemic activity in this area started at week 42 in 2009, peaked at week 49 and ended at week 2 in 2010 [19]. The isolates for the 2007/08 season were collected in northern France between week 44 (29 October) in 2007 and week 3 (14 January) in 2008 and those for the 2008/09 season between week 45 (3 November) in 2008 and week 4 (19 January) in 2009.

One of the 2007/08 seasonal influenza A(H1N1) viral isolates, (A/Paris/1149/2008), was included in most experiments (12/13, due to a technical problem in one) as a control to assess the reproducibility of our experimental conditions. A further 12 seasonal influenza A(H1N1) viral isolates from 2007/08, either susceptible or resistant to oseltamivir, and five seasonal influenza A(H1N1) viral isolates from 2008/09, all resistant to oseltamivir, were also included. These seasonal viral isolates were chosen at the beginning and peak of the influenza seasons in northern France, as for the pandemic isolates, and, for the 2007/08 seasonal isolates, we also took into account the co-circulation of viruses sensitive or naturally resistant to oseltamivir.

Among the 23 pandemic influenza A(H1N1) viral isolates included in our study, we defined two distinct groups of viruses according to the disease severity of the patients (Table1). Information about the existence of underlying conditions prone to increase disease severity was noted when available (Table 1). Severe influenza cases were those who were hospitalised in an intensive care unit or died as a result of their infection. Patients with mild disease were matched as much as possible by the week and geographical area of collection.

Two representative isolates from the human North American triple reassortant influenza A(H1N1) viruses (A/Illinois/09/2007 and A/Ohio/02/2007) and from the swine Eurasian influenza A(H1N1) and Hong Kong triple reassortant internal gene (TRIG) influenza A(H1N2) lineages (A/Swine/Cotes d’Armor/0231/2006 and A/Swine/Hong Kong/1578/2003) [20], respectively, were tested in parallel.

Table 1. Origin and characteristics of 2009 pandemic influenza A(H1N1) viral isolates from mild and severe influenza cases, northern France, 24 September–16 December 2009 (weeks 39–51) (n=23)



Preparation and analysis of viral isolates
In order to produce suitable viral stocks, all isolates were amplified by two serial passages at a multiplicity of infection of 10–3 plaque forming units per cell at 35 °C in MDCK cells in serum-free minimal essential medium (MEM) containing 1µg/ml trypsin treated with L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK). We assumed that the pandemic viral isolates would be able to grow efficiently at 35 °C (as the temperature of the human upper respiratory tract is about 33 °C) and we therefore chose to amplify the virus at 35 °C rather than 37°C in order to avoid the preselection of variants that grow preferentially at high temperature. Viral stocks were clarified and aliquots for single use were kept frozen at –80 °C.

Viral RNA was prepared using the QIAamp Viral RNA Mini Kit (Qiagen). Reverse transcription PCR was carried out using the SuperScript One-Step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen) and oligonucleotides specific for the haemagglutinin (HA) and NA segments. The amplicons were sequenced using a Big Dye terminator sequencing kit and an automated sequencer (Applied Biosystems). In some cases, pyrosequencing was used to determine specifically the sequence at residue 222 of the HA or at residue 275 of the NA. For the H275Y mutation, the primers GRswN1-780Fw/090206 (5'-GGGGAAGATTGTYAAATCAGTYGA-3') and GRswN1-1273Rv/090207 (5'-biotin-CWACCCAGAARCAAGGYCTTATG-3') were used for amplification, and GRswN1-804Fw/090208 (5'-GYTGAATGCMCCTAATT-3') for sequencing, as previously described [21]. For the D222G mutation, the primers GRswH1-672Fw (5'-CAAGAAGTTCAAGCCGGAAATAGC-3') and GRswH1-821 Rv (5'-biotin-ATTGCGAATGCATATCTCGGTAC-3') were used for amplification, and GRswH1-693Fw (5'-AGCAATAAGACCCAAAG-3') for sequencing. Primers were designed using the Pyrosequencing Assay Design Software (Biotage). Pyrosequencing reactions were performed on purified biotinylated amplicons as previously described [22].

Temperature-sensitivity assays
Confluent three-day-old cultures of MDCK cells in 96-well plates, prepared in MEM containing 5% foetal calf serum and 50 µg/ml gentamycin, were washed twice with serum-free MEM before infection. Serum-free MEM (170 µl/well) containing trypsin-TPCK (1µg/ml) and gentamycin (50 µg/ml) were added to cultures. Ten-fold dilutions of each virus sample in MEM (30 µl/well, 10 wells/dilution, 3 plates/virus sample) were added to cells. Plates were sealed with an adhesive membrane and covered with lids and incubated at 34 °C, 37 °C and 40 °C. Incubators were used for incubation at 34 °C and 37 °C, whereas a water bath was used to incubate plates at exactly 40 °C.

Cytopathic effects were observed under the microscope three days after infection and virus titres as 50% tissue culture infectious doses (TCID50) per mL were determined as previously described by Reed and Muench [23]. The reproductive capacity at the high, potentially restrictive temperature of 40 °C (RCT40 value) is the difference, in log values, between the titres at 40 °C and at 37 °C for each viral isolate. Similarly, the reproductive capacity at 34 °C (RCT34 value) is the difference in log values between the viral titres at 34 °C and at 37 °C. Both RCT values are expressed as the mean ± standard deviation (SD) from at least three independent experiments.

Results

For all isolates tested, viral titres were similar at 34°C and 37°C; the RCT34 values varied between –0.63±0.53 and +0.50±0.16 (Figure). In contrast, significant differences were observed between isolates grown at 40 °C, since the RCT40 values varied between 0.00±0.16 and –4.23±0.42. The RCT40 value of the pool of 2007/08 and 2008/09 seasonal viruses varied between –2.40±0.29 and –3.97±0.12, indicating that the titres of these viruses were about 250- to 9,300-fold lower at 40 °C than at 37 °C. The pandemic viruses showed RCT40 values ranging from –1.30±0.29 to –4.23±0.42, indicating that their titres were about 20- to 17,000-fold lower at 40 °C than at 37 °C.

Figure. Reproductive capacity of 2009 pandemic influenza A(H1N1) viral isolates (n=23) and 2007/08 and 2008/09 seasonal influenza A(H1N1) viral isolates (n=18) at 34 °C and 40 °C, relative to 37 °C, northern France



On average, pandemic viral isolates were about three-fold less sensitive at 40 °C than the pool of the 2007/08 and 2008/09 seasonal viruses (RCT40 values of –2.55±0.82 and –3.06±0.46, respectively; p<0.05, Student's t-test) and showed a significantly higher variability in temperature sensitivity (variance ratio: 3.18; p<0.025, Fisher’s exact test). No statistically significant differences were seen in RCT40 values regardless of whether the pandemic viral isolates had been isolated from severe cases with or without underlying condition (n=15) or from mild cases (n=8) (Table 2).

Table 2. Reproductive capacity of 2009 pandemic influenza A(H1N1) viral isolates (n=23) and 2007/08 and 2008/09 seasonal influenza A(H1N1) viral isolates (n=18) at 34 °C and 40 °C, northern France


 
Interestingly, two human isolates representative of the North American triple reassortant influenza A(H1N1) viruses (A/Illinois/09/2007 and A/Ohio/02/2007) grew similarly at 40 °C and 37 °C (Table 2). Their growth was thus clearly more resistant to high temperature than that of the pandemic viral isolates. The Hong Kong TRIG swine influenza A(H1N2) and Eurasian swine influenza A(H1N1) viruses included in our study showed an intermediate phenotype between the triple reassortant and pandemic viruses (Table 2 and Figure).

A D222G substitution in the receptor binding site of HA was seen in two of the viral isolates included in our study (isolates 20097101 and 20097105). This substitution has been detected sporadically, with some degree of correlation between the presence of the substitution and the severity of the disease [24-27]. Isolates 20097101 and 20097105 showed RCT40 values of –2.25±0.57 and –1.33±0.12, respectively (data not shown). The 20097101 virus was isolated from the brain of a young patient who died after infection and showed a G residue at position 222 of the HA (Table 1). The viruses detected in the initial brain specimen showed a D at this position, but probably contained a low, undetectable fraction of viruses of the HA-222G genotype upon amplification in MDCK cells.

The 20097097 virus isolated from the lung of the same patient showed a D residue at position 222 of the HA (Table 1). No statistically significant difference in temperature sensitivity was observed between the 20097101 and 20097097 isolates.

One of the pandemic viral isolates (20097214) included in our study had the H275Y substitution in the NA (Table 1) that is associated with oseltamivir resistance [28,29] and was characterised by a marked sensitivity to high temperature, with an RCT40 value of –3.90±0.57. However, the two panels of oseltamivir-resistant and -sensitive seasonal isolates from 2007/08 showed no statistically significant difference in temperature sensitivity (Table 2 and Figure). Overall, our results suggest that neither the D222G substitution in the HA nor the H275Y substitution in the NA have a major impact on the viral sensitivity to high temperature.

The NA and M gene sequences of the 23 pandemic viral isolates included in our study were determined: the Global Initiative on Sharing Avian Influenza Data (GISAID) accession numbers are shown in Table 3. The NA and M1 amino acid sequences of the 23 pandemic viral isolates included in our study were were aligned with the corresponding sequences of the swine and triple reassortant viruses. The pandemic virus-derived sequences showed very few variations: their NA and M1 sequence shared about 91% and 94% identity with the respective Eurasian swine virus-derived sequences and 81% and 88% identity with the respective triple reassortant virus-derived sequences.

Table 3. GISAID accession numbers of 2009 pandemic influenza A(H1N1) viral isolates, northern France (n=23)

 

Discussion and conclusion

A panel of seasonal and pandemic influenza A(H1N1) viral isolates from northern France in 2007/08 to 2008/09 grew with similar efficiency at 34 °C and 37 °C, suggesting that these viruses are well adapted to the physiological temperatures of the upper and lower respiratory tract. In contrast, they replicated less efficiently at 40 °C than at 37 °C. As compared with seasonal isolates, the pandemic viral isolates showed a marked heterogeneity in temperature sensitivity as indicated by a significantly higher variability in the corresponding RCT40 values. This heterogeneity probably reflects ongoing evolution and genetic diversification of the virus since its introduction in the human population in April 2009.

The sensitivity to high temperature of isolates of the pandemic virus from severe cases of influenza was not statistically significantly different from that of isolates from mild cases, but the numbers were small. These results suggest that there was little or no correlation between temperature sensitivity of pandemic viruses and clinical severity. However, this finding should be confirmed by analysing a larger panel of viruses, given the strong heterogeneity in temperature sensitivity, the possible bias due to the fact that the severity of the disease in up to 25% of severe cases during the pandemic was due to bacterial secondary infections rather than the characteristics of the pandemic virus [30,31] and the fact that host factors, such as underlying conditions identified as risk factors, seem to have contributed substantially to the clinical course of severe cases with 2009 pandemic influenza A(H1N1) [32,33].

The Eurasian swine influenza A(H1N1) virus, a Hong Kong TRIG swine influenza A(H1N2) virus and two A(H1N1) triple reassortant viruses included in our study showed a lower sensitivity to elevated temperature (40 °C) than the pandemic and seasonal viral isolates on average, in agreement with the fact that the normal body temperature of pigs varies between 38.5 °C and 39.2 °C [34]. All the pandemic viral isolates included in our study replicated less efficiently at 40 °C than did the triple reassortant viruses although their genomic segments, except for the NA and matrix (M) segments, are phylogenetically related to the triple reassortants.

No specific sequence signature was observed for the viruses that showed the highest RCT40 (data not shown). Overall, our observations suggest that the sensitivity to high temperature of the pandemic viral isolates is determined by complex gene constellation and/or mutation effects.

In conclusion, our small dataset shows that the pandemic viruses that circulated in northern France in 2009 were more heterogeneous with respect to their ability to grow at high temperature (40 °C) than the seasonal viruses that circulated there in 2007/08 and 2008/09. They point to the impact of viral temperature sensitivity on the genetic evolution and diversification of the pandemic virus during the first year after its introduction into the human population and they call for a close monitoring of this phenotypic marker related to host and tissue tropism during the coming years.


Acknowledgements

We are indebted to the members of the GROG and Réseau National des Laboratoires (RENAL) sentinel networks who provided the specimens from which viruses were isolated. We thank G. Simon (French Agency for Food, Environmental and Occupational Health & Safety (ANSES, Ploufragan, France), M. Peiris (The University of Hong Kong, Hong Kong) and N. Cox (Centers for Disease Control and Prevention (CDC), Atlanta, United States) for providing the swine and triple reassortant strains. We gratefully acknowledge the contribution of the members of the National Influenza Center (Northern-France), Mathilde Benassaya, David Briand, Frédérique Cuvelier, Sébastien Legal, Jennifer Martinez, Vanessa Roca and Jessy Vandekerkhove for isolation and characterisation of the viruses. This work was funded by the Institut Pasteur and by the European Community's Seventh Framework Programme (FP7/2007-2013) under the project ‘European Management Platform for Emerging and Re-emerging Infectious disease Entities’ (EMPERIE) EC grant agreement number 223498.


References

  1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 18;360(25):2605-15.
  2. Naffakh N, van der Werf S. April 2009: an outbreak of swine-origin influenza A(H1N1) virus with evidence for human-to-human transmission. Microbes Infect. 2009;11(8-9):725-8.
  3. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459(7249):931-9.
  4. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197-201.
  5. Olsen CW. The emergence of novel swine influenza viruses in North America. Virus Res. 2002;85(2):199-210.
  6. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med. 2009;360(25):2616-25.
  7. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28(31):4895-902.
  8. Richman DD, Murphy BR. The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev Infect Dis. 1979;1(3):413-33.
  9. Mackenzie J. Virulence of temperature-sensitive mutants of influenza virus. Br Med J. 1969;3(5673):757-8.
  10. Sabin A, Lwoff A. Relation between reproductive capacity of polioviruses at different temperatures in tissue culture and neurovirulence. Science. 1959;129:1287-8.
  11. Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Minor P, et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol. 1990;64(10):4922-9.
  12. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med.1966;122(3):800-4.
  13. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56(1):152-79.
  14. Webster RG, Yakhno M, Hinshaw VS, Bean WJ, Murti KG. Intestinal influenza: replication and characterization of influenza viruses in ducks. Virology. 1978;84(2):268-78.
  15. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, et al. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog. 2007;3(10):1374-9.
  16. Massin P, van der Werf S, Naffakh N. Residue 627 of PB2 is a determinant of cold sensitivity in RNA replication of avian influenza viruses. J Virol. 2001;75(11):5398-404.
  17. Massin P, Kuntz-Simon G, Barbezange C, Deblanc C, Oger A, Marquet-Blouin E, et al. Temperature sensitivity on growth and/or replication of H1N1, H1N2 and H3N2 influenza A viruses isolated from pigs and birds in mammalian cells. Vet Microbiol. 2009 19;142(3-4):232-41.
  18. Husseini RH, Sweet C, Collie MH, Smith H. Elevation of nasal viral levels by suppression of fever in ferrets infected with influenza viruses of differing virulence. J Infect Dis. 1982;145(4):520-4.
  19. Vaux S, Brouard C, Fuhrman C, Turbelin C, Cohen J, Valette M, et al. Dynamique et impact de l'épidémie A(H1N1)2009 en France métropolitaine, 2009-2010 [Dynamics and impact of the A(H1N1)2009 epidemic in metropolitan France, 2009-2010]. Bulletin Epidémiologique Hebdomadaire. 2010;24-25-26:259-66. French. Available from: http://www.invs.sante.fr/beh/2010/24_25_26/beh_24_25_26_2010.pdf
  20. Vijaykrishna D, Smith GJ, Pybus OG, Zhu H, Bhatt S, Poon LL, et al. Long-term evolution and transmission dynamics of swine influenza A virus. Nature. 201126;473(7348):519-22.
  21. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother. 2010;54(3):1102-10.
  22. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(9492):1175-81.
  23. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493-7.
  24. Drews SJ, Pabbaraju K, Wong S, Tokaryk KL, May-Hadford J, Lee B, et al. Surveillance of autopsy cases for D222G substitutions in haemagglutinin of the pandemic (H1N1) 2009 virus in Alberta, Canada. Clin Microbiol Infect. 2011;17(4):582-4.
  25. Ikonen N, Haanpää M, Rönkkö E, Lyytikäinen O, Kuusi M, Ruutu P, et al. Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland. PLoS One. 2010;5(10):e13329.
  26. Kilander A, Rykkvin R, Dudman SG, Hungnes O. Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill. 2010;15(9):pii=19498. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19498
  27. Mak GC, Au KW, Tai LS, Chuang KC, Cheng KC, Shiu TC, et al. Association of D222G substitution in haemagglutinin of 2009 pandemic influenza A (H1N1) with severe disease. Euro Surveill. 2010;15(14);15(14):pii=19534. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19534
  28. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004;103(1-2):199-203.
  29. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother. 2002;46(12):3809-16.
  30. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177(1):166-75.
  31. Viasus D, Paño-Pardo JR, Pachón J, Campins A, López-Medrano F, Villoslada A, et al. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect. 2011;17(5):738-46.
  32. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 Influenza A (H1N1) Infection: a global pooled analysis. PLoS Med. 2011;8(7):e1001053.
  33. Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis. 2011;52(4):457-65.
  34. Ingram DL, Mount LE. The metabolic rates of young pigs living at high ambient temperatures. Res Vet Sci. 1965;6:300-6.


Back to Table of Contents
Previous Download (pdf) Next

Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.